ORMP vs. IOBT, GNLX, ABEO, PRPH, PMVP, ANIX, ALLK, VACC, DMAC, and SLS
Should you be buying Oramed Pharmaceuticals stock or one of its competitors? The main competitors of Oramed Pharmaceuticals include IO Biotech (IOBT), Genelux (GNLX), Abeona Therapeutics (ABEO), ProPhase Labs (PRPH), PMV Pharmaceuticals (PMVP), Anixa Biosciences (ANIX), Allakos (ALLK), Vaccitech (VACC), DiaMedica Therapeutics (DMAC), and SELLAS Life Sciences Group (SLS). These companies are all part of the "pharmaceutical preparations" industry.
IO Biotech (NASDAQ:IOBT) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, community ranking, valuation and earnings.
54.8% of IO Biotech shares are held by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 3.5% of IO Biotech shares are held by company insiders. Comparatively, 12.0% of Oramed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
IO Biotech's return on equity of -7.15% beat Oramed Pharmaceuticals' return on equity.
Oramed Pharmaceuticals received 302 more outperform votes than IO Biotech when rated by MarketBeat users. However, 86.67% of users gave IO Biotech an outperform vote while only 74.82% of users gave Oramed Pharmaceuticals an outperform vote.
Oramed Pharmaceuticals has higher revenue and earnings than IO Biotech. IO Biotech is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, IO Biotech and IO Biotech both had 2 articles in the media. IO Biotech's average media sentiment score of 1.38 beat Oramed Pharmaceuticals' score of 0.50 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media.
IO Biotech currently has a consensus price target of $8.33, suggesting a potential upside of 486.85%. Given Oramed Pharmaceuticals' higher probable upside, equities research analysts plainly believe IO Biotech is more favorable than Oramed Pharmaceuticals.
IO Biotech has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500.
Summary
Oramed Pharmaceuticals beats IO Biotech on 10 of the 14 factors compared between the two stocks.
Get Oramed Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ORMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oramed Pharmaceuticals Competitors List
Related Companies and Tools
